EXAS insider trading
NasdaqCM HealthcareEXACT SCIENCES CORP: insider trade history from SEC Form 4 filings.
About EXACT SCIENCES CORP
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Company website: www.exactsciences.com
EXAS insider activity at a glance
FilingIQ tracks 1,142 insider transactions for EXAS in filings since Jan 5, 2015. The most recent transaction is dated Mar 23, 2026.
Across the full history, 9 open-market purchases
and 450 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on EXAS insider trades is 65.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest EXAS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for EXAS?
- FilingIQ tracks 1,142 Form 4 insider transactions for EXAS (EXACT SCIENCES CORP), covering filings from Jan 5, 2015 onwards. 0 of those are dated within the last 90 days.
- Are EXAS insiders net buyers or net sellers?
- Across the full Form 4 history for EXAS, 9 transactions (1%) were open-market purchases and 450 (39%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does EXAS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is EXAS in?
- EXACT SCIENCES CORP (EXAS) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $19.77B.
Methodology & sources
Every EXAS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.